Is the Mounjaro jab safe? What the evidence actually says

Step 1 — Before the first jab: what a prescriber screens for

The safety conversation starts before you ever pick up a pen. Any legitimate clinical assessment will look at your medical history, current medicines and any conditions that make tirzepatide unsuitable. A personal history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 is a contraindication. Active or recurrent pancreatitis, certain gallbladder conditions and severe gastrointestinal disease all require careful prescriber discussion. Pregnancy, breastfeeding and trying to conceive are clear reasons the medicine is not recommended.

There is a common assumption that because Mounjaro is widely discussed, it must be straightforward to use. If you are wondering whether Mounjaro is safe to use given your own circumstances, the answer depends on factors a prescriber needs to assess individually. Women taking oral contraceptives need to know that tirzepatide can reduce pill absorption; adding a barrier method for the first four weeks of treatment and for four weeks after each dose increase is the guidance NHS England provides. The clinical team at nume covers all of this as part of the consultation, not as an afterthought.

Identity and weight verification also happen before any prescription is written. That step matters because the dose you start on and how quickly you move up depends on where you are now, not where you'd like to be.

Step 2, Starting treatment: the side effects most people actually experience

For most people the jab's side-effect story is a gastrointestinal one, and it is loudest in the first few weeks. Nausea is the most commonly reported effect; vomiting, diarrhoea, constipation, reflux and burping all appear on the list too. The NHS medicines page for tirzepatide notes these are generally mild to moderate and tend to ease as your body adjusts. Fatigue and headache show up in some people, and injection-site redness or mild soreness is fairly routine.

Starting at 2.5mg (the first four-week pen) exists precisely to give your system time to settle before any increase. The detail on what each side effect feels like and how long it tends to last is worth reading before you begin, so nothing catches you off guard. If you want a fuller picture of the complete side-effect profile across all doses, that resource covers it thoroughly.

Exercise during treatment is a separate question some people raise. Changes in energy, dizziness on exertion and timing meals around activity can all shift on tirzepatide; the interaction between Mounjaro and exercise is its own topic, and one worth discussing with your prescriber if you train regularly.

Step 3, When to get medical help without delay

This section matters most. Certain symptoms during Mounjaro treatment need prompt attention, not a wait-and-see approach.

Pancreatitis: the MHRA's Drug Safety Update from January 2026 specifically flagged acute pancreatitis as an infrequent but serious risk with GLP-1 receptor agonist medicines including tirzepatide. The signal to act on is severe stomach pain that does not ease, particularly if it radiates toward your back, with or without vomiting. Call 999 or go to A&E, do not wait for it to pass on its own.

Gallbladder symptoms: upper-right abdominal pain, especially after eating, can point to gallbladder problems; get this assessed promptly.

Signs of dehydration: if vomiting or diarrhoea is severe enough that you cannot keep fluids down, kidney strain can follow quickly. Seek medical help rather than pushing through.

Allergic reaction: facial swelling, difficulty breathing or a widespread rash after injecting needs emergency care immediately.

Low mood or thoughts of self-harm: these have been reported with weight-loss medicines; tell your prescriber or GP, or contact a mental health service, do not dismiss it.

If you experience anything unexpected and are unsure, the aftercare team at nume is available seven days a week. Any suspected side effect can also be reported to the MHRA through the Yellow Card scheme, reports from patients are taken seriously and contribute to ongoing safety monitoring.

Step 4, Keeping perspective: what the trial evidence and regulators concluded

The SURMOUNT clinical programme, which informed the MHRA's approval, involved thousands of adults across multiple trials. The safety data from those studies, reviewed by both the MHRA and NICE as part of the TA1026 appraisal published in December 2024, concluded that the benefit-risk balance supports use for eligible adults. That is not the same as saying the medicine is risk-free, it means the risks are understood, manageable and outweighed by the benefits for the right candidates.

NICE's guidance covers which adults are eligible and under what conditions treatment should be reassessed. For a broader view of the overall safety picture, or to compare it with how side effects compare across different weight-loss jabs, those pages go further than this one can. The short version: Mounjaro is a regulated, evidence-backed medicine. Used under proper clinical supervision, with prescriber oversight at every repeat, the risk picture is well understood. That supervision is the safety net.

If you'd like to understand whether you are a suitable candidate, our prescribers discuss exactly this during a free consultation. Check your eligibility here, it takes a few minutes and there's no obligation.